. 2012 Jun 1;17(6):6684–6696. doi: 10.3390/molecules17066684

Table 4.

Anti-SA and anti-MRSA activity of chalcones in combination with antibiotics.

Mix ^a	MSSA ATCC 25923					MRSA ATCC 43300
	MICs (µg/mL)		FICI	Interpretation	Increasing rate (fold) ^b	MICs (µg/mL)		FICI	Interpretation	Increasing rate (fold) ^b
	Alone	Mix ^a	FICI	Interpretation	Increasing rate (fold) ^b	Alone	Mix ^a	FICI	Interpretation	Increasing rate (fold) ^b
p₆	64	32	0.75	Additive		ND	ND	ND	ND	ND
Cipro	0.5	0.125	0.75	Additive		ND	ND	ND	ND	ND
p₆	ND	ND	ND	ND	ND	128	32	0.31	Synergistic	4
Vanco	ND	ND	ND	ND	ND	1	0.0625	0.31	Synergistic	16
f₅	ND	ND	ND	ND	ND	64	16	0.31	Synergistic	4
Oxa	ND	ND	ND	ND	ND	2	0.125	0.31	Synergistic	16
f₆	128	64	0.75	Additive	2	ND	ND	ND	ND	ND
Cipro	0.5	0.125	0.75	Additive	4	ND	ND	ND	ND	ND
f₆	ND	ND	ND	ND	ND	128	64	0.625	Additive	2
Vanco	ND	ND	ND	ND	ND	1	0.125	0.625	Additive	8
f₆	ND	ND	ND	ND	ND	128	64	0.56	Additive	2
Oxa	ND	ND	ND	ND	ND	2	0.125	0.56	Additive	16
t₅	32	32	1.06	Indifferent	1	ND	ND	ND	ND	ND
Ery	0.5	0.03	1.06	Indifferent	1.67	ND	ND	ND	ND	ND
t₅	32	16	1	Additive	2	ND	ND	ND	ND	ND
Cipro	0.5	0.25	1	Additive	2	ND	ND	ND	ND	ND
t₅	ND	ND	ND	ND	ND	64	32	1.0	Additive	2
Vanco	ND	ND	ND	ND	ND	1	0.5	1.0	Additive	2
t₅	ND	ND	ND	ND	ND	64	32	0.56	Additive	2
Oxa	ND	ND	ND	ND	ND	2	0.125	0.56	Additive	16

^(a) Mix = Combination; ^(b) Rate in increasing antibacterial activity of antibiotic/chalcone in combination compared to that of in alone (fold); ND = not dertemined. Vanco: vancomycin; Cipro: ciprofloxacin; Ery: erythromycin; Oxa: oxacillin.